AnaptysBio Inc
ANAB
NASDAQ
Biotechnology
$58.47
USD
+2.45 (+4.37%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $1.69B
Volume 330.8K
Revenue
$232.39M
TTM
+107.7%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-26.79M
TTM
+81.0%
YoY
Operating Cash Flow
$4.48M
TTM
+104.1%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 27.8 | 22.3 | 76.3 | 108.2 | 25.6 |
YoY Growth | +286.8% | +102.9% | +154.3% | +151.1% | -8.0% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 27.8 | 22.3 | 76.3 | 108.2 | 25.6 |
Selling, General & Administrative | 14.1 | 10.6 | 10.2 | 15.8 | 26.2 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 55.3 | 48.4 | 41.6 | 41.3 | 60.2 |
Operating Income | -27.5 | -26.2 | 34.7 | 66.9 | -34.6 |
EBITDA | -27.4 | -26.0 | 34.8 | 67.0 | -34.5 |
Other Income / Expense | 1.9 | 3.5 | 0.0 | -0.0 | -0.0 |
Total Other Income / Expense | -11.7 | -12.4 | -19.6 | -17.2 | -18.2 |
Income Before Income Taxes | -39.3 | -38.6 | 15.1 | 49.7 | -52.8 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 |
Net Income | -39.3 | -38.6 | 15.1 | 49.6 | -52.9 |
Consolidated Net Income / Loss | -39.3 | -38.6 | 15.1 | 49.6 | -52.9 |
Net Income Attributable to Common Shareholders | -39.3 | -38.6 | 15.1 | 49.6 | -52.9 |
Basic EPS | -$1.28 | -$1.34 | $0.54 | $1.79 | -$1.84 |
Diluted EPS | -$1.28 | -$1.34 | $0.52 | $1.87 | -$1.84 |
Basic Shares Outstanding | 30.6M | 28.8M | 27.8M | 27.7M | 28.7M |
Diluted Shares Outstanding | 30.6M | 28.8M | 29.0M | 26.6M | 28.7M |